(Q39621183)

13 September 2017

title

18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy (English)

1 reference

13 September 2017

18F-FPPRGD2 and 18F-FDG PET of Response to Abraxane Therapy (English)

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Fluorodeoxyglucose Positron Emission Tomography

19 November 2024

main subject

1 reference

based on heuristic

inferred from title

fluorine radioisotopes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21149494

19 November 2024

fludeoxyglucose (18F)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21149494

19 November 2024

9

Xiaoyuan Chen

1 reference

13 September 2017

8

Gang Niu

1 reference

13 September 2017

4

Qizhen Cao

1 reference

13 September 2017

3

Shuanglong Liu

1 reference

13 September 2017

2

Yongjun Yan

1 reference

13 September 2017

Xilin Sun

1

1 reference

13 September 2017

Min Yang

5

1 reference

13 September 2017

Nouri Neamati

6

1 reference

13 September 2017

Baozhong Shen

7

1 reference

13 September 2017

language of work or name

English

0 references

publication date

13 December 2010

1 reference

full work available at URL

13 September 2017

https://jnm.snmjournals.org/content/jnumed/52/1/140.full.pdf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21149494

http://jnm.snmjournals.org/cgi/content/abstract/52/1/140

19 November 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21149494

https://syndication.highwire.org/content/doi/10.2967/jnumed.110.080606

19 November 2024

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

The Journal of Nuclear Medicine

19 November 2024

published in

1 reference

13 September 2017

volume

52

1 reference

13 September 2017

issue

1

1 reference

13 September 2017

page(s)

140-146

1 reference

Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: combining drugs imposes different artificial checkpoints

13 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy

19 November 2024

2

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase I study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinica

19 November 2024

3

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Pharmacogenomics of paclitaxel

19 November 2024

4

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges

19 November 2024

5

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

19 November 2024

6

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

19 November 2024

7

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel

19 November 2024

8

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer

19 November 2024

9

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

The microtubule-affecting drug paclitaxel has antiangiogenic activity

19 November 2024

10

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly

19 November 2024

11

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma

19 November 2024

12

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Vascular integrins: therapeutic and imaging targets of tumor angiogenesis

19 November 2024

13

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Integrins in cancer: biological implications and therapeutic opportunities

19 November 2024

14

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

New insights in vascular development: vasculogenesis and endothelial progenitor cells

19 November 2024

15

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Evaluating integrin function in models of angiogenesis and vascular permeability

19 November 2024

16

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Multimodality molecular imaging of tumor angiogenesis

19 November 2024

17

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Multimodality imaging of tumor integrin alphavbeta3 expression

19 November 2024

18

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer

19 November 2024

19

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

In vivo molecular imaging of myocardial angiogenesis using the αvβ3 integrin-targeted tracer 99mTc-RAFT-RGD

19 November 2024

20

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Microglia are mediators of Borrelia burgdorferi-induced apoptosis in SH-SY5Y neuronal cells

19 November 2024

21

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression

19 November 2024

22

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Specific targeting of human integrin α(v)β (3) with (111)In-labeled Abegrin™ in nude mouse models

19 November 2024

24

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer

19 November 2024

25

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein

19 November 2024

26

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Has molecular and cellular imaging enhanced drug discovery and drug development?

19 November 2024

27

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers

19 November 2024

28

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

(68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging

19 November 2024

29

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

(64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression

19 November 2024

30

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4)

19 November 2024

31

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Imaging of integrins as biomarkers for tumor angiogenesis

19 November 2024

32

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy

19 November 2024

34

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib

19 November 2024

35

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography

19 November 2024

37

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

PET of EGFR antibody distribution in head and neck squamous cell carcinoma models

19 November 2024

38

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma

19 November 2024

39

1 reference

https://api.crossref.org/works/10.2967/JNUMED.110.080606

19 November 2024

Identifiers

1 reference

13 September 2017

1 reference